Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) Accounts Payables (2016 - 2023)

Rapid Therapeutic Science Laboratories' Accounts Payables history spans 8 years, with the latest figure at $769957.0 for Q2 2023.

  • For Q2 2023, Accounts Payables rose 9.27% year-over-year to $769957.0; the TTM value through Jun 2023 reached $769957.0, up 9.27%, while the annual FY2022 figure was $891408.0, 91.62% up from the prior year.
  • Accounts Payables for Q2 2023 was $769957.0 at Rapid Therapeutic Science Laboratories, up from $734833.0 in the prior quarter.
  • Across five years, Accounts Payables topped out at $1.2 million in Q1 2022 and bottomed at $19652.0 in Q1 2019.
  • The 5-year median for Accounts Payables is $117804.0 (2019), against an average of $357602.6.
  • The largest annual shift saw Accounts Payables skyrocketed 2570.15% in 2022 before it tumbled 38.74% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $117082.0 in 2019, then decreased by 4.09% to $112298.0 in 2020, then soared by 314.26% to $465204.0 in 2021, then surged by 91.62% to $891408.0 in 2022, then dropped by 13.62% to $769957.0 in 2023.
  • Per Business Quant, the three most recent readings for RTSL's Accounts Payables are $769957.0 (Q2 2023), $734833.0 (Q1 2023), and $891408.0 (Q4 2022).